Crinetics Pharmaceuticals Announced Topline Results From PATHFNDR-2 Phase 3 Trial Of Paltusotine For Acromegaly Achieving The Primary And All Secondary Endpoints; NDA Submission To FDA Expected In 2H 2024
Author: Benzinga Newsdesk | March 19, 2024 06:06am